Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCRT and Intensive Chemotherapy for Rectal Cancer with Metastases
NCT01923987Phase 2Unknown
- Sponsor
- Korea Cancer Center Hospital
- Start
- Aug 2012
- Primary completion
- Dec 2020
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, fluorouracil, bevacizumab, KL-140 in rectal cancer, liver metastases, lung metastases (LM), sponsored by Korea Cancer Center Hospital. Status: unknown.
02
Drugs
oxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabfluorouracilbevacizumabKL-140
03
Conditions
rectal cancerliver metastaseslung metastases (LM)
Beyond the preview
Go deeper on NCT01923987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01923987.